The aim of the study was to evaluate the efficacy of the new cephalosporin cefuroxime in patients with urinary tract infections. Other important criteria were the overall tolerance, estimated by biochemical and hematological parameters. The local tolerance at the site of injection was also of special interest.
Materials and Methods
Twenty-six patients with acute or chronic urinary tract infections took part in this study. There were 17 males and 9 females, aged from 32-84 years. Three patients also suffered from pneumonia. All patients were uniformly treated with 3 x 750 mg of cefuroxime daily by i.v. injection, except 6 patients who were additionally given 2.5 mg/kg/day of gentamicin. The mean period of treatment was 8 days (4-15 days).
Blood samples were taken prior to the commencement of therapy, daily during therapy, and on the eighth day and twenty-eighth day after the end of treatment. For the analysis of the urinary parameters and for the bacteriology, urine samples were collected prior to treatment, twice weekly during treatment, and on the eighth and twentyeighth days after therapy. The samples were taken either by suprapubic puncture or by catheter. An infection was considered to exist if there were more than 105 organisms/mi. The samples were assayed by the agar diffusion test using discs impregnated with 30 ,ug of cefuroxime and a strain of Escherichia coli as standard. Incubation was for 12 h at 37°C. Three patients with pneumonia had sputum samples collected by transtracheal aspiration and bacteriologically assayed in the same manner.
For the purpose of this study the data were evaluated on the basis of a simplified interpretation. Blood parameters and biochemical data were assessed as being Below (B), Normal (N), or Above (A) the standard range. Data were interpreted either as B, N or A prior to and during the treatment. The bacteriological susceptibility was judged either as Sensitive (S) or Resistant (R).
The therapeutic response was estimated either as cured, improved, improved with relapse, failure, or no comment. Improved meant reduction in the number of organisms to < 106/ml. (Table 1) Before the beginning of treatment, 29 organisms were cultured from urine samples, including 3 mixed infections caused by 2 organisms. In 3 other cases organisms were cultured both from urine and from sputum. Twenty-two of the 29 pathogens examined were sensitive to cefuroxime. During the treatment with cefuroxime 15 of 29 strains of bacteria were eradicated. Moderate success was obtained against 6 strains. In 4 strains, which previously appeared to be resistant to cefuroxime, the therapy failed. A change of pathogens with participation of the original bacteria occurred in 3 cases during therapy, whereas a complete change was seen in 1 case.
RESULTS

Bacteriological Evaluation
Three further cases could not be evaluated (Table   2 ).
Responses to Therapy
The response to treatment with cefuroxime is shown in Table 4 . The summary of the clinical response is shown in Table 3 . Overall andLocal Tolerance Table 5 shows that there was a minimal change in the biochemical parameters. Only in 1 case was there a slight elevation of bilirubin, and in serum glutamic oxaloacetic and glutamic pyruvic transaminases. Most of the data were similar to the initial values, or changed to normal. The same impression was obtained from the blood para-meters (Table 6) . Sometimes there was a slight increase of WBC but in general, these parameters remained or became normal. As far as urinary parameters are concerned (Table 7) , in 1 case there was a decrease in leucocytes, and in 8 cases a decrease of the erythrocytes to normal values. The rest remained unchanged.
Only 7 patients reported slight pain at the site of injection and described it as being 'mild'. Pain persisted for 5 min in 1 case, 2 min in 3 cases, and 1 min in 3 cases.
Summary and Conclusions
The efficacy of cefuroxime was evaluated clinically and bacteriologically in 26 patients with urinary tract infections. The dosage was 3 x 750 mg of cefuroxime daily by i.v. injection. Twenty-nine causative Gram positive or Gram negative organisms, of which 22 were found to be sensitive to cefuroxime, were isolated from urine samples, Table 4 Clinical results
Indication
Daily mainly collected by suprapubic puncture. In 6 cases cefuroxime was administered in combination with gentamicin. The clinical and bacteriological results of this study lead to the conclusion that cefuroxime is an efficient antibiotic which permits monotherapy in many cases where previously a combination therapy was indicated. Moreover, it is possible to make use of the combination with aminoglycosides because of the superior renal tolerance of cefuroxime. In all cases, cefuroxime was well tolerated both overall and at the injection site.
